January 21, 2026
Contact: Benjamin Butz, Director of Membership and Stakeholder Engagement
Phone: (202) 222-0905
Email: ben.butz@fdli.org

Food and Drug Law Institute Announces New Board Member and Executive Committee Updates

Washington, DC – The Food and Drug Law Institute (FDLI) is pleased to announce the appointment of Stacy Amin, Oracle; Winston Kirton, BakerHostetler; and Elizabeth Oestreich, ELIQUENT Life Sciences, to its Board of Directors. The appointees join 13 other highly respected leaders in the food and drug law field in serving on the FDLI Board.

Stacy Amin is Vice President and Chief Counsel for Global Health Regulatory and Policy at Oracle, where she leads the Oracle Health & Life Sciences legal, regulatory, and policy teams. Previously, she served as Chief Counsel of the U.S. Food and Drug Administration, as Senior Counsel to the President in the White House Counsel's Office, and as Chief Counsel of the Senate HELP Committee. Immediately before joining Oracle, she chaired Morrison Foerster's global Health and Life Sciences Regulatory & Compliance practice, advising pharma, biotech, and medtech clients on their most complex challenges and strategic priorities. She has a J.D. from Harvard Law School and a B.A. from George Washington University, and she clerked on the U.S. Court of Appeals for the 8th Circuit.

Winston S. Kirton co-leads Baker & Hostetler's FDA Practice, as well as the Life Sciences Industry team. He advises both domestic and international companies that are facing regulatory challenges involving products and services regulated by the FDA, including biopharmaceuticals, medical devices, foods, dietary supplements, cosmetics, and enabling technologies. His practice focuses on corporate transactions, research and development, manufacturing and supply chain, and commercial regulatory and compliance matters. He also advises clients on business and legal strategies and disputes related to third-party contract manufacturing relationships, third-party supplier relationships, and alliance-partner relationships.

Winston previously served as the head of compliance and ethics, while based in London, for a multinational U.S. pharmaceutical company, and was responsible for business units comprised of Latin America, Central and Eastern Europe, Middle East-Asia-India, China, and the Pacific Rim regions.

Elizabeth Oestreich is Senior Vice President, Regulatory Compliance at ELIQUENT Life Sciences, where she brings a diverse background of legal, public policy, and non-profit sector knowledge to her position. Liz provides strategic guidance on premarket and postmarket issues, specifically related to regulatory compliance. She works with pharmaceutical and medical device clients to prepare for FDA inspections and to address and remediate compliance matters. She advises clients on FDA communications, including 483 and warning letter responses, and offers guidance on agency expectations and regulatory policy.

Prior to joining ELIQUENT (formerly Greenleaf Health), Liz served as Director of Educational Programming for the Food and Drug Law Institute (FDLI). Before earning her law degree, Liz worked as a government relations professional for the Society of Chemical Manufacturers and Affiliates (SOCMA). She earned a B.S. in Political Science from the University of Arizona and a J.D. from the University of the District of Columbia's David A. Clarke School of Law.

In addition, FDLI announces that Scott D. Danzis, Covington & Burling, LLP, has been moved to Vice Chair. Also serving on the Executive Committee are Chair, Vernessa Pollard, DLA Piper LLP; Secretary and General Counsel, Amy Norris, Nordic Naturals; Treasurer, Melanie K. Gross, Genentech, Inc; and Christine M. Simmon, President and CEO, FDLI.

FDLI thanks outgoing Directors Freddy A. Jimenez, Celldex Therapeutics; Ricardo Carvajal, Hyman, Phelps & McNamara, PC; and David C. Spangler, Consumer Healthcare Products Association. Each made invaluable contributions to FDLI and the broader food and drug law community through their Board service.

The Food and Drug Law Institute (FDLI) is a nonprofit membership organization that offers education, training, publications, and professional networking opportunities in the field of food and drug law. As a neutral convener, FDLI provides a venue for stakeholders to inform public policy, law, and regulation.